Broadcast date: 29 May 2013, Wednesday
Time: 9.00-10.00 AM PT/ 18.00-19.00 CET
Come and join our CEO, Attila Berces online in a presentation and demo of how Omixon Target HLA typing will bring you value during the analysis of NGS data.
Currently, there are 69 on-going clinical trials investigating HLA as a potential biomarker for safety or efficacy. It appears that beside being the most important marker in transplantation, HLA is becoming a more important biomarker for cancer therapeutic development as well. The analytical performance of NGS-based genetic tests highly depends on the bioinformatics software. Although the current false variant rate can be acceptable for research market, it is simply unsuitable for making clinical decisions. Omixon tailors the analysis for the sequencer, amplification method, primer kit, and the characteristics of the gene target itself. This approach results in a robust and highly accurate method to identify genetic variants.
In this webinar you will learn:
- How to reduce ambiguity and increase resolution
- How to achieve the highest accuracy
- How to use Omixon Target HLA as an HLA-typing tool
- How to increase efficiency by reducing effort, time and cost
Who should attend?
- Scientists and researchers from HLA-typing labs
- Molecular biologists working with NGS
- Medical professionals working in transplantation,oncology and immunology
- Bioinformathics working in transplantaion, oncology and immunology
Presenting: Attila Berces, PhD, CEO of Omixon Biocomputing
A live Q&A session will follow the presentation, offering you the opportunity to put forward your questions.
Reserve your webinar seat here.
